Oncobiologics (NASDAQ:OTLK) vs. Structure Therapeutics (NASDAQ:GPCR) Head-To-Head Comparison

Oncobiologics (NASDAQ:OTLK) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, dividends, analyst recommendations and risk.

Risk and Volatility

Oncobiologics has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.35, meaning that its stock price is 235% less volatile than the S&P 500.

Profitability

This table compares Oncobiologics and Structure Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
Structure Therapeutics	N/A	-24.91%	-23.67%

Earnings and Valuation

This table compares Oncobiologics and Structure Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35 million	168.68	-$62.42 million	($1.17)	-1.39
Structure Therapeutics	N/A	N/A	-$141.20 million	($0.87)	-56.19

Oncobiologics has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Oncobiologics and Structure Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1	5	1	0	2.00
Structure Therapeutics	2	1	12	3	2.89

Oncobiologics currently has a consensus price target of $6.50, suggesting a potential upside of 299.75%. Structure Therapeutics has a consensus price target of $110.55, suggesting a potential upside of 126.12%. Given Oncobiologics’ higher possible upside, equities analysts plainly believe Oncobiologics is more favorable than Structure Therapeutics.

Summary

Structure Therapeutics beats Oncobiologics on 7 of the 13 factors compared between the two stocks.

About Oncobiologics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

About Structure Therapeutics

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.